It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Collisions of the transcription and replication machineries on the same DNA strand can pose a significant threat to genomic stability. These collisions occur in part due to the formation of RNA-DNA hybrids termed R-loops, in which a newly transcribed RNA molecule hybridizes with the DNA template strand. This study investigated the role of RAD52, a known DNA repair factor, in preventing collisions by directing R-loop formation and resolution. We show that RAD52 deficiency increases R-loop accumulation, exacerbating collisions and resulting in elevated DNA damage. Furthermore, RAD52’s ability to interact with the transcription machinery, coupled with its capacity to facilitate R-loop dissolution, highlights its role in preventing collisions. Lastly, we provide evidence of an increased mutational burden from double-strand breaks at conserved R-loop sites in human tumor samples, which is increased in tumors with low RAD52 expression. In summary, this study underscores the importance of RAD52 in orchestrating the balance between replication and transcription processes to prevent collisions and maintain genome stability.
Collisions of transcription and replication machineries on the same DNA strand threaten genomic stability. Here, the authors show that RAD52 prevents these collisions by regulating R-loop formation and resolution. RAD52 deficiency leads to increased R-loops, exacerbated collisions, DNA damage, and higher mutational burden in tumors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 MSKCC, Department of Radiation Oncology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
2 MSKCC, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
3 MSKCC, Department of Radiation Oncology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); MSKCC, Human Oncology and Pathogenesis, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
4 University of Bern, Department for BioMedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); Swiss Institute of Bioinformatics, SIB, Lausanne, Switzerland (GRID:grid.419765.8) (ISNI:0000 0001 2223 3006)
5 MSKCC, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); AstraZeneca, Gaithersburg, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493)
6 MSKCC, Department of Radiation Oncology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); MSKCC, Molecular Biology Program, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)